Therapy of aggressive pituitary tumors

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1561-1570

  Colao, Annamaria ^a   Grasso, Ludovica F S ^a   Pivonello, Rosario ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

aggressive pituitary tumor; chemotherapy; medical treatment; pituitary adenoma; pituitary carcinoma; radiotherapy; surgery

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BIM 23 A 760; BROMOCRIPTINE; CABERGOLINE; CHIMERIC PROTEIN; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; GROWTH HORMONE; KETOCONAZOLE; LOMUSTINE; METHOTREXATE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PROCARBAZINE; PROLACTIN; PROOPIOMELANOCORTIN; QUINAGOLIDE; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE; THYROTROPIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACROMEGALY; ACTH SECRETING ADENOMA; ADJUVANT THERAPY; AGGRESSIVE PITUITARY TUMOR; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM METASTASIS; CHRONIC FATIGUE SYNDROME; CUSHING DISEASE; CYBERKNIFE; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOCRINE SURGERY; EXTERNAL BEAM RADIOTHERAPY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS TUMOR; IMMUNOMODULATION; IN VITRO STUDY; ISOTOPE LABELING; LOW DRUG DOSE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROLACTINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC RADIOSURGERY; SURVIVAL; THYROTROPIN SECRETING ADENOMA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION;

ADENOMA; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; PROGNOSIS; PROLACTINOMA; TREATMENT FAILURE;

EID: 79958758987     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.568478     Document Type: Review

References (92)

1. Kaltsas GA, Grossman AB. Malignant pituitary tumors. Pituitary 1998;1:69-81
2. Scheithauer BW, Gaffey TA, Lloyd RV, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006;59:341-53 (Pubitemid 44325877)
3. Selman WR, Laws ER, Scheithauer BW, et al. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-7 (Pubitemid 16035061)
4. Hornyak M, Couldwell WT. Multimodality treatment for invasive pituitary adenomas. Postgrad Med 2009;121(2):168-76
5. Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 2009;12(3):256-60
6. Kaltsas GA, Panagiotis N, Kontogeorgos G, et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-99 (Pubitemid 40686369)
7. Lopes MB, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine 2005;28:115-21 (Pubitemid 43004809)
8. Gurlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 2007;156:143-53 (Pubitemid 46554508)
9. Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011;114(2):336-44
10. Lloyd RJ, Kovacs K, Young WF Jr, et al. Tumours of the pituitary gland. Pathology and Genetics. In: DeLellis RA, Lloyd RV, Heitz PU, editors, Tumours of Endocrine Tumours. International Agency for Research and Cancer (IARC), Lyon; 2004. p. 9-48
11. Saeger W, Ludecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J of Endocrinol 2007;156:203-16 (Pubitemid 46554515)
12. Kaltsas GA, Mukherjee JJ, Plowman PN, et al. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumours. J Clin Endocrinol Metab 1998;83:4233-8 (Pubitemid 29100114)
13. Meij BP, Lopes MB, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002;96:195-208 (Pubitemid 34230231)
14. Greenman Y, Woolf P, Coniglio J, et al. Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastases detected by 111-indium pentetreotide scan. J Clin Endocrinol Metab 1996;81:1628-33 (Pubitemid 26118604)
15. Vaquero J, Herrero J, Cincu R. Late development of frontal prolactinoma after resection of pituitary tumor. J Neurooncol 2003;64:255-8 (Pubitemid 37203466)
16. Pivonello R, Ferone D, Lombardi G, et al. Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007;156(Suppl):13-21
17. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534 (Pubitemid 44213229)
18. Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007;156(2):225-31 (Pubitemid 46554517)
19. Popovic EA, Vattuone JR, Siu KH, et al. Malignant prolactinomas. Neurosurgery 1991;29:127-30
20. Thapar K, Kovacs K, Muller P. Clinical-pathologic correlations of pituitary tumors. Baillieres Clin Endocrinol Metab 1995;9:243-70
21. Walker JD, Grossman AB, Anderson JV, et al. Malignant prolactinoma with extracanial metastases: a report of three cases. Clin Endocrinol 1993;38:411-19 (Pubitemid 23105075)
22. Hurel SJ, Harris PE, McNicol AM, et al. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;82:2962-5 (Pubitemid 27385656)
23. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primari therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006;91(6):2112-18 (Pubitemid 43854991)
24. Petrossians P, Borges-Martin L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6 (Pubitemid 40185454)
25. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: long-term (up to nine years) prospective study af its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
26. Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM 230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89(6):3027-32 (Pubitemid 38766404)
27. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM 230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45 (Pubitemid 38269871)
28. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286(1-2):69-74 (Pubitemid 351680237)
29. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with Acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010;95(6):2781-9
30. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary dependent Cushings disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22
31. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J of Endocrinol 2005;152:645-54 (Pubitemid 40575811)
32. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide Alone or with Cabergoline and Ketoconazole in Cushings Disease. N Engl J Med 2010;362:19
33. Drake WM, Parkinson C, Besser GM, et al. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab 2001;12:408-13 (Pubitemid 33714238)
34. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor anatgonist pegvisomant. N Engl J Med 2000;342:1171-7 (Pubitemid 30211048)
35. Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol 2009;161(Suppl 1):S3-S10
36. Gruszka A, Ren SG, Dong J, et al. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007;148(12):6107-14 (Pubitemid 350146153)
37. Saveanu A, Gunz G, Guillen S, et al. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006;83(3-4):258-63 (Pubitemid 44578880)
38. Florio T, Barbieri F, Spaziante R, et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 2008;15(2):583-96 (Pubitemid 351880845)
39. Peverelli E, Olgiati L, Locatelli M, et al. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett 2010;288(2):170-6
40. Prasad D. Clinical results of conformal radiotherapy and radiosurgery for pituitary adenoma. Neurosurg Clin N Am 2006;17:129-41
41. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-8 (Pubitemid 23168470)
42. Imboden PNE, Borruat FX, De Tribolet N, et al. Non-functioning pituitary carcinoma. Pituitary 2004;7:149-56 (Pubitemid 43336602)
43. Martin NA, Hales M, Wilson CB. Cerebellar metastases from a prolactinoma during treatment with bromocriptine. J Neurosurg 1981;55:615-19 (Pubitemid 12227595)
44. Epstein A, Epstein BS, Molho L, et al. Carcinoma of the pituitary gland with metastases to the spinal cord and roots of the cauda equina. J Neurosurg 1964;21:846-53
45. Cartwright DM, Miller TR, Nasr AJ. Fine needl aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopathol 1994;11:68-73 (Pubitemid 24258816)
46. Walker JD, Grossman A, Anderson JV, et al. Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 1993;38(4):411-19 (Pubitemid 23105075)
47. Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90:800-4 (Pubitemid 40279200)
48. Brada M, Ford D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992;304:1343-6
49. Evans DGR, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumors after therapeutic radiation for benign disease: substantial risks in certain tumor prone syndromes. J Med Genet 2006;43:289-94
50. Swords FM, Allan CA, Plowman PN, et al. Stereotactic radiosurgery. XVI. A treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab 2003;88:5334-40 (Pubitemid 37452736)
51. Castro DG, Cecilio SAJ, Canteras MM. Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety. Radiat Oncol 2010;5:109
52. Rowland NC, Aghi MK. Radiation treatment strategies for acromegaly. Neurosurg Focus 2010;29(4):E12
53. Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009;94:3400-7
54. Castinetti F, Regis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 2010;6:214-23
55. Choi JY, Chang JH, Chang JW, et al. Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery. Yonsei Med J 2003;44:602-7 (Pubitemid 37098879)
56. Hockaday TD, Laing AH, Welbourn RB, Hartog M. Letter: proton beam therapy for acromegaly. BMJ 1975;1:457
57. Kjellberg RN, Kliman B. Bragg peak proton treatment for pituitary-related conditions. Proc R Soc Med 1974;67:32-3
58. Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005;102:678-91, 28 (Pubitemid 43186673)
59. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995;25:272-8
60. Kaltsas G, Rockall A, Papadogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004;151:15-27 (Pubitemid 39117361)
61. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 1998;10:58-65 (Pubitemid 28039243)
62. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92-7 (Pubitemid 30665946)
63. Hofland LJ, de Herder WW, Waaijers M, et al. Interferon-alfa-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab 1999;84:3336-43 (Pubitemid 30646965)
64. Kaltsas GA, Mukherjee JJ, Plowman PN, et al. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83:4233-8 (Pubitemid 29100114)
65. Labeur M, Refojo D, Wolfel B, et al. Interferon-g inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. J of Endocrinol 2008;199:177-89
66. Vaughan NJA, Laroche CM, Goodman I, et al. Pituitary Cushings disease arising from a previously non-functional corticotrophic chromophobe adenoma. Clin Endocrinol (Oxf) 1985;22:147-53 (Pubitemid 15173978)
67. Kasperlik-Zaluska AA, Wislawski J, Kaniewska J, et al. Cytostatics for acromegaly: marked improvement in a patient with an invasive pituitary tumour. Acta Endocrinol (Copenh) 1987;116:347-9 (Pubitemid 17154198)
68. Kaizer FE, Orth DN, Mukai K, et al. A pituitary parasellar tumour with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides. J Clin Endocrinol Metab 1983;57:649-53 (Pubitemid 13005537)
69. Peterson T, McFarlane IA, McKenzie JM, et al. Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychol 1992;55:1205-6
70. Mixson AJ, Friedman TC, Katz DA, et al. Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 1993;76:529-33 (Pubitemid 23073087)
71. Assai A, Matsutani M, Nobuaki F, et al. Malignant growth hormone-secreting pituitary adenoma with haematogenous dural metastasis: case report. Neurosurgery 1988;22:1091-4
72. Gollard R, Kosty M, Cheney C, et al. Prolactin secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. Cancer 1995;76:1814-20
73. Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006;105:621-6 (Pubitemid 44525896)
74. Lim S, Shahinian H, MMaya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006;7:518-20 (Pubitemid 43796152)
75. Zhu Y, Shahinian H, Hakimian B, et al. Temodar: novel treatment for pituitary carcinoma. US Endocr Soc 2004;138:43-5
76. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 2007;38:185-9 (Pubitemid 44880216)
77. Syro LV, Uribe H, Penagos LC, et al. Antitumor effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol 2006;65:549-53
78. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51 (Pubitemid 30238234)
79. Stupp R, Gander M, Leyvraz S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2001;2:552-60 (Pubitemid 33586868)
80. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of 0-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4 (Pubitemid 38375541)
81. Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J of Endocrinol 2010;163(6):843-51
82. Bode H, Seiz M, Lammert A, et al. SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases. Exp Clin Endocrinol Diabetes 2010;118(10):760-3
83. Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary [Epub ahead of print]
84. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide. Cancer 2010;117(3):454-62
85. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-65
86. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4 (Pubitemid 38375541)
87. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4
88. Takeshita A, Inoshita N, Taguchi M, et al. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushings disease. Eur J Endocrinol 2009;161(4):553-9
89. Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 2008;115(2):261-2
90. McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009;71(2):226-33
91. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a french multicenter experience. J Clin Endocrinol Metab 2010;95(10):4592-9
92. Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression. J Clin Endocrinol Metab 2010;95(11):E280-90